Skip to main content

Table 1 IC50s for 5 viruses and comparison of FC and pNL4-3 wt

From: Characterization of two HIV-1 infectors during initial antiretroviral treatment, and the emergence of phenotypic resistance in reverse transcriptase-associated mutation patterns

Virus

EC50 a ± SD (nM) (FCb)

NNRTIs

NRTIs

AZT

EFV

3TC

d4T

WTpNL4-3

24.80 ± 12.83

14.90 ± 0.35

25.46 ± 3.90

197.87 ± 7.93

V179E/Y181C/H221Y

T215Y

273.43 ± 108.18(11.02)

83.04 ± 25.00 (5.57)**

427.03 ± 225.85 (16.77)

880.20 ± 299.01 (4.04)

V179E/Y181C

T215Y

382.50 ± 216.51 (15.42)c

62.94 ± 3.58 (4.23)**

622.10 ± 82.10 (24.43)**

1048.73 ± 229.18 (5.30)c

V179E/H221Y

T215Y

1950.67 ± 688.66 (78.65)**

52.48 ± 3.44 (3.52) c

1304.30 ± 304.75 (51.22)**

2170.00 ± 494.11 (10.97)**

V179E

T215Y

501.00 ± 95.98 (20.20)**

34.41 ± 11.97 (2.31)

240.77 ± 34.68 (9.46)c

1031.33 ± 350.34 (5.21)c

K103N/Y181C/H221Y

T215Y

1337.67 ± 89.49 (53.94)**

503.47 ± 207.80 (33.79)**

807.70 ± 123.88 (31.72)**

7462.67 ± 900.25 (37.72)**

K103N/Y181C

T215Y

52.78 ± 6.79 (2.13)

122.07 ± 12.24 (8.19)**

139.67 ± 41.81 (5.49)

420.60 ± 125.31 (2.13)

K103N/H221Y

T215Y

1393.00 ± 100.80 (56.17)**

154.63 ± 30.80 (10.38)**

264.73 ± 42.13 (10.40)**

422.27 ± 46.19 (2.13)

K103N

T215Y

88.00 ± 12.48 (3.55)

392.70 ± 74.88 (26.36)**

141.60 ± 62.63 (5.56)

471.93 ± 66.35 (2.39)

  1. athe 50 % inhibitory concentration
  2. bcalculated by dividing the IC50 of each mutant virus by the IC50 for the wild-type. Mean ± SD of three independent experiments
  3. cIC50 was significantly changed compared with pNL4-3 wt
  4. P < 0.05; “**” denotes P < 0.01